Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Public health market trends

Public_Health

Public Health 2025 Review: Prevention Under Pressure and Signals Too Loud to Ignore

In 2025, public health entered a paradoxical phase: unprecedented scientific…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Hematology Today—February 16, 2026
Oncology Video Recap—February 16, 2026
Oncology Today—February 16, 2026
Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal oncology $1.5B deal
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL

Tags

AA Signature Abbott Abeona Therapeutics ACTH-dependent Cushing’s Adrenal disorders AI in ophthalmology C4 Therapeutics CD19 CD19 CAR-T chronic obstructive pulmonary disease companion diagnostics CVD DYNE-251 Enanta ERβ ligands federated learning graphene devices Growth hormone deficiency HGPS IVUS JASCAYD Kesimpta Lexeo Therapeutics LGMD2i MedinCell methotrexate neuromuscular disease Novo Medi Sciences One Medical Organoids Parkway Radiology Partners Health Management Pascal pericarditis Phase 2 protocol-based HTN diabetes care Rein Therapeutics Semble sleep and brain health syndax pharmaceuticals SynKIR-110 talkspace University of Oslo Verily warrants

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Hematology Today—February 16, 2026
Oncology Video Recap—February 16, 2026
Oncology Today—February 16, 2026
Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal oncology $1.5B deal
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL

TAGS

AA Signature Abbott Abeona Therapeutics ACTH-dependent Cushing’s Adrenal disorders AI in ophthalmology C4 Therapeutics CD19 CD19 CAR-T chronic obstructive pulmonary disease companion diagnostics CVD DYNE-251 Enanta ERβ ligands federated learning graphene devices Growth hormone deficiency HGPS IVUS JASCAYD Kesimpta Lexeo Therapeutics LGMD2i MedinCell methotrexate neuromuscular disease Novo Medi Sciences One Medical Organoids Parkway Radiology Partners Health Management Pascal pericarditis Phase 2 protocol-based HTN diabetes care Rein Therapeutics Semble sleep and brain health syndax pharmaceuticals SynKIR-110 talkspace University of Oslo Verily warrants

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy